OncoMatch/Clinical Trials/NCT07005128
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Is NCT07005128 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Tarlatamab and Durvalumab for small-cell lung cancer.
Treatment: Tarlatamab · Durvalumab · Carboplatin · Etoposide — The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Saint Bernards Medical Center · Jonesboro, Arkansas
- Translational Research in Oncology US Inc, Trio Central Pharmacy · Los Angeles, California
- University of California Los Angeles · Santa Monica, California
- Presbyterian Intercommunity Hospital Health Whitter Hospital · Whittier, California
- Colorado West Healthcare System dba Grand Valley Oncology · Grand Junction, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify